Press Releases

06.26.2025

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors

06.25.2025

Pfizer Declares Third-Quarter 2025 Dividend

06.25.2025

Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

06.02.2025

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

05.31.2025

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

05.30.2025

Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

05.22.2025

Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer

05.19.2025

Pfizer Enters into Exclusive Licensing Agreement with 3SBio

04.29.2025

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

04.26.2025

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

04.24.2025

Pfizer Announces 2025 Shareholder Meeting Preliminary Results

04.23.2025

Pfizer Declares Second-Quarter 2025 Dividend